LifeArc

LifeArc is a leading UK-based medical research charity specializing in translating early scientific discoveries into new drugs and diagnostics. It has played key roles in the humanization of several blockbuster monoclonal antibodies now on the market—including pembrolizumab ("Keytruda"), natalizumab ("Tysabri"), tocilizumab ("Actemra"), and vedolizumab ("Entyvio")—and continues to invest heavily in rare disease research, neurodegeneration, childhood cancers, chronic infections and global health. The organization provides funding for academic projects and early ventures while offering expertise in IP management, drug discovery support (antibody/small molecule), diagnostics development and technology transfer. Profits are reinvested into further research.